Morepen LaboratoriesNSE:MOREPENLAB +2.00%74 Quick Ratio is 1.82 as of Mar. 2026, which is 94% above its 10-year median of 0.94. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 74/100 and a GF Value™ of ₹49.82 (Fairly Valued). The stock has 5 warning signs investors should review. Among 997 Drug Manufacturers companies, Morepen Laboratories ranks better than 60.88% on this metric.
Morepen Laboratories has a quick ratio of 1.82. It generally indicates good short-term financial strength.
The historical rank and industry rank for Morepen Laboratories's Quick Ratio or its related term are showing as below:
NSE:MOREPENLAB'
s Quick Ratio Range Over the Past 10 Years
Min: 0.39 Med: 0.94 Max: 1.82
Current: 1.82
During the past 13 years, Morepen Laboratories's highest Quick Ratio was 1.82. The lowest was 0.39. And the median was 0.94.
NSE:MOREPENLAB's Quick Ratio is ranked better than 60.88% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs NSE:MOREPENLAB: 1.82
Morepen Laboratories (NSE:MOREPENLAB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Morepen Laboratories Quick Ratio Related Terms
Morepen Laboratories Quick Ratio Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Morepen Laboratories's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories (NSE:MOREPENLAB) has a Quick Ratio of 1.82 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Morepen Laboratories and its competitors. This is 94% above median its historical median of 0.94. Over the past decade, Morepen Laboratories' Quick Ratio has ranged from 0.39 to 1.82. According to the industry distribution chart, Morepen Laboratories ranks #390 out of 997 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is Morepen Laboratories' Quick Ratio too high?
Morepen Laboratories' current Quick Ratio of 1.82 is 94% above median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 1.82. The Drug Manufacturers industry median Quick Ratio is 1.45. Morepen Laboratories' value of 1.82 is 25.5% above this industry median. Based on the distribution chart, Morepen Laboratories ranks #390 out of 997 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #390 out of 997 companies for Quick Ratio. This puts Morepen Laboratories in the upper half of its industry. The industry median Quick Ratio is 1.45. Morepen Laboratories' value of 1.82 is 25.5% above this benchmark. Historically, Morepen Laboratories' own Quick Ratio has ranged from 0.39 to 1.82 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 1.45, Morepen Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current Quick Ratio of 1.82 is 25.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current Quick Ratio is 1.82, which is 94% above median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹49.82, compared to a current price of ₹53.16 — trading 6.7% above its estimated fair value. The current Quick Ratio is 1.82, which is 94% above median its 10-year median of 0.94 and 25.5% above the Drug Manufacturers industry median of 1.45. Morepen Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Quick Ratio is 1.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹53.16 is trading 6.7% above its estimated GF Value™ of ₹49.82.
GuruFocus considers Morepen Laboratories to be Fairly Valued.
Key valuation signals for NSE:MOREPENLAB:
Quick Ratio: 1.82 (94% above median its 10-year median of 0.94)
GF Value™: ₹49.82 vs. price of ₹53.16 (6.7% above fair value)
Industry Position: 25.5% above the Drug Manufacturers median (#390 of 997)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
74GF Score
Get the complete analysis for NSE:MOREPENLAB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
